ProMIS Neurosciences, Inc. (PMN)Healthcare | Biotechnology | Toronto, Canada | NasdaqCM
12.80 USD
-1.45
(-10.175%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 12.80 |
Hot Take ↕ | July 11, 2026, 4:58 a.m. EDT
The immediate outlook is neutral-to-slightly-bearish due to a lack of clear directional edge, despite a recent price bounce off the lows. The stock has surged nearly 45% in the last two weeks, moving from roughly $10 to $14.25, which suggests some short-term momentum, but the underlying business fundamentals are severely compromised. The company is burning significant cash with negative operating and free cash flows, and the balance sheet is deteriorating rapidly. The most critical red flag is the multi-year price trajectory: the asset has lost over 94% of its value since 2016, with four consecutive years of negative annual returns ending in a massive 81.5% drop last year. This structural decline indicates that the market has permanently reassessed the business quality downward, rendering any 'value' narrative moot. Furthermore, there is no dividend income to offset the capital loss, and the company recently raised $175 million just to extend its runway, highlighting a desperate need for capital rather than sustainable profitability. While analysts project a 230% upside, this appears to be a speculative bet on a future catalyst rather than a reflection of current operational reality. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.055459 |
| AutoETS | 0.055461 |
| MSTL | 0.069271 |
| AutoTheta | 0.266563 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 23% |
| H-stat | 5.33 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 3.56 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 114,786,472 |
| Forward P/E | -5.36 |
| Beta | -0.21 |
| Website | https://www.promisneurosciences.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.096153855 |
| Address1 | 1,920 Yonge Street |
| Address2 | Suite 200 |
| All Time High | 2,580.0 |
| All Time Low | 6.27 |
| Ask | 16.79 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 81,190 |
| Average Daily Volume3 Month | 36,877 |
| Average Volume | 36,877 |
| Average Volume10Days | 81,190 |
| Beta | -0.211 |
| Bid | 10.21 |
| Bid Size | 2 |
| Book Value | 6.771 |
| City | Toronto |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 12.8 |
| Current Ratio | 9.919 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 14.7599 |
| Day Low | 12.8 |
| Display Name | ProMIS Neurosciences |
| Earnings Timestamp End | 1,754,569,800 |
| Earnings Timestamp Start | 1,754,569,800 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 50,938,372 |
| Eps Current Year | -8.241 |
| Eps Forward | -2.3876243 |
| Eps Trailing Twelve Months | -16.53 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.9662 |
| Fifty Day Average Change | 1.8338003 |
| Fifty Day Average Change Percent | 0.16722295 |
| Fifty Two Week Change Percent | 9.615385 |
| Fifty Two Week High | 39.75 |
| Fifty Two Week High Change | -26.95 |
| Fifty Two Week High Change Percent | -0.67798746 |
| Fifty Two Week Low | 6.27 |
| Fifty Two Week Low Change | 6.53 |
| Fifty Two Week Low Change Percent | 1.0414673 |
| Fifty Two Week Range | 6.27 - 39.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,168,439,400,000 |
| Float Shares | 4,597,467 |
| Forward Eps | -2.3876243 |
| Forward P E | -5.3609776 |
| Free Cashflow | -18,816,976 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 10 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -33,379,320 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11846 |
| Held Percent Institutions | 0.74367 |
| Implied Shares Outstanding | 8,967,693 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,764,288,000 |
| Last Split Factor | 1:25 |
| Long Business Summary | ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada. |
| Long Name | ProMIS Neurosciences, Inc. |
| Market | us_market |
| Market Cap | 114,786,472 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_11795000 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -40,615,616 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 114,786,470 |
| Number Of Analyst Opinions | 6 |
| Open | 14.11 |
| Operating Cashflow | -35,575,232 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 416 847 6898 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 12.8 |
| Post Market Time | 1,783,973,404 |
| Previous Close | 14.25 |
| Price Eps Current Year | -1.5532095 |
| Price Hint | 2 |
| Price To Book | 1.8904151 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.689 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.28571 |
| Region | US |
| Regular Market Change | -1.45 |
| Regular Market Change Percent | -10.1754 |
| Regular Market Day High | 14.7599 |
| Regular Market Day Low | 12.8 |
| Regular Market Day Range | 12.8 - 14.7599 |
| Regular Market Open | 14.11 |
| Regular Market Previous Close | 14.25 |
| Regular Market Price | 12.8 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 75,806 |
| Return On Assets | -0.62998 |
| Return On Equity | -1.15732 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 8,967,693 |
| Shares Percent Shares Out | 0.0227 |
| Shares Short | 203,926 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 188,790 |
| Short Name | ProMIS Neurosciences Inc. |
| Short Percent Of Float | 0.0229 |
| Short Ratio | 6.67 |
| Source Interval | 15 |
| State | ON |
| Symbol | PMN |
| Target High Price | 48.19872 |
| Target Low Price | 18.11981 |
| Target Mean Price | 32.317303 |
| Target Median Price | 34.096596 |
| Total Cash | 63,848,096 |
| Total Cash Per Share | 7.12 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -16.53 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 11.83125 |
| Two Hundred Day Average Change | 0.96875 |
| Two Hundred Day Average Change Percent | 0.081880614 |
| Type Disp | Equity |
| Volume | 75,806 |
| Website | https://www.promisneurosciences.com |
| Zip | M4S 3E2 |